Artwork

コンテンツは Discovery Matters によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Discovery Matters またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Discovery Matters

シェア
 

Manage series 2508237
コンテンツは Discovery Matters によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Discovery Matters またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
A collection of stories and insights on matters of discovery that advance life sciences. Brought to you by the curious people at Cytiva.
  continue reading

100 つのエピソード

Artwork

Discovery Matters

17 subscribers

updated

iconシェア
 
Manage series 2508237
コンテンツは Discovery Matters によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Discovery Matters またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
A collection of stories and insights on matters of discovery that advance life sciences. Brought to you by the curious people at Cytiva.
  continue reading

100 つのエピソード

すべてのエピソード

×
 
In this special celebratory milestone episode, we mark our 100th episode with a vibrant recap of year. Get ready to dive into fascinating conversations, from the squirrely intelligence of cephalopods and their chameleon-like abilities to cutting-edge antibody drug conjugates (ADCs) revolutionizing cancer treatment, to an enlightening chat with Nobel Laureate Dr. Michael Houghton on the crucial path to combating hepatitis C.…
 
Insulin's discovery in 1921 transformed diabetes from a certain death sentence to a manageable chronic condition, revolutionizing modern medicine. In this episode of Discovery Matters , we look back to our episode on a fascinating journey through 100 years of insulin advancements and its profound impact on diabetes treatment. Listen in to appreciate 100 years of ground-breaking science and anticipate what the future holds for diabetes treatment.…
 
In this episode of Discovery Matters we delve into groundbreaking advancements in Parkinson’s disease research. Dodi and Conor transport us to the frontier of medical innovation, exploring the latest discoveries and techniques that hold promise for early diagnosis and treatment of Parkinson’s disease. Show notes • Decet, Marianna et al. ‘ A candidate loss-of-function variant in SGIP1 causes synaptic dysfunction and recessive parkinsonism’ , Cell Reports Medicine, Volume 5, Issue 10. • Hällqvist, J., Bartl, M., Dakna, M. et al. ‘ Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset’ . Nat Commun 15, 4759 (2024). • Roald Dahl's Marvellous Children's Charity Keywords : non-invasive procedure, early diagnosis, synaptic homeostasis, Parkinsonism, biomarkers, machine learning, REM sleep disorder, inflammatory pathways, dopaminergic cells, predictive diagnostics, early intervention.…
 
As we approach our one hundredth episode, travel back with us to the origins of the podcast in our premiere episode, "Team and Jam and Protein Separation." In this debut, we explored the vital process of protein separation—an essential technique in biochemistry and pharmaceuticals that continues to impact human health in significant ways.…
 
Dive into the fascinating world of virology as we welcome Nobel Prize-winning virologist Dr. Michael Houghton on this episode of Discovery Matters. We explore Dr. Houghton's groundbreaking work in identifying the hepatitis C virus (HCV) and his enduring quest to combat this global health threat. From the monumental discovery of HCV in 1982 to the revolutionary diagnostic tests that nearly eradicated transfusion-related hepatitis C by the mid-1990s, Dr. Houghton provides an engaging and insightful journey through decades of scientific innovation. Show notes Richard D Roberts, Patrick C Kyllonen, ‘Morningness–eveningness and intelligence: early to bed, early to rise will likely make you anything but wise!’ Personality and Individual Differences, Volume 27, Issue 6, 1999. https://doi.org/10.1016/S0191-8869(99)00054-9 . Taquet, MaximeLone, Nazir et al. ‘Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.’ The Lancet Psychiatry, Volume 11, Issue 9. https://doi.org/10.1016/S2215-0366(24)00214-1…
 
Eco-design, collaboration, circular economy. These are the bywords of sustainability in biopharma. Join Ryan Walker, Senior Director of Sustainability at Cytiva, and Aude Arkham, Global Head of Eco Design and Circular Economy at Sanofi, as they explore how eco-design and circular economy initiatives are shaping the future of healthcare. We delve into challenges, achievements, and the transformational potential of sustainability efforts within biopharma. From Sanofi’s life cycle assessments to industry-wide data difficulties, this episode navigates the complex landscape of creating greener solutions without compromising innovation and compliance.…
 
In this episode of "Discovery Matters," we dive into the powerful intersection of big data and artificial intelligence. Joined by Matej Macak, a partner from McKinsey, we unravel how AI and machine learning are revolutionizing our approach to finding new, effective medications. With Tom Yankeelov, Professor of Biomedical Engineering, Diagnostic Medicine, Oncology at the University of Texas for Austin, we'll explore the "problem of averages" and much more.…
 
What does 'the body as a bioreactor' mean? In this discussion how scientists use the body's machinery to produce therapeutic proteins. Scott Ripley, General Manager of Nucleic Acids at Cytiva, explains that traditional bioprocessing uses external bioreactors, while the new approach leverages the body's natural processes. This method offers benefits like longer protein half-life and the ability to express multiple proteins simultaneously. Justin Eyquem, assistant professor at University of California San Francisco, discusses the potential of in vivo CAR T cell therapy, which could simplify manufacturing and reduce costs. Both approaches face challenges in quality assurance and regulatory approval but hold promise for personalized and more effective treatments.…
 
We're diving into advanced therapies with industry leaders. Emmanuel Abate, President of Genomic Medicine at Cytiva discussed the strategies to accelerate clinical work and reduce costs. Nathaniel Wang, CEO and Co-Founder of Replicate Bioscience highlighted their ground breaking self-replicating RNA technology, showcasing impressive clinical results for a rabies vaccine. Both experts emphasized the momentum in biotech, the potential of AI in advancing science, and the importance of making innovative therapies accessible globally. Stay tuned for these insights. Show notes Beneath Everest, a lone caretaker struggles to keep one of the world’s highest laboratories alive Integrating human endogenous retroviruses into transcriptome-wide association studies highlights novel risk factors for major psychiatric conditions Keywords : vaccines, advanced therapies, mRNA, manufacturing, technology, patients, innovation, new modalities.…
 
From gene and cell therapies, to the use of CRISPR and other precision engineering technologies, this episode dives into the opportunities and challenges of the emerging field of advanced therapies. On Discovery Matters this week, Dodi and Conor are joined by Daria Donati, Chief Scientific Officer of Genomic Medicine at Cytiva, as well as Jen Moody, Vice President of External Innovation of Genomic Medicines at Danaher, to discuss the science, progress, and potential of advanced therapeutics. Demaris Mills, Group Executive of Genomic Medicines at IDT, and experts Fyodor Urnov, Professor of Molecular and Cell Biology at the University of California, Berkeley, and the Director of Technology & Translation at the Innovative Genomics Institute, cover the technologies used in gene and cell therapies as well as CRISPR to deliver powerful and precise treatments aiming for a healthier future.…
 
Can you tell the difference between a human and AI? Of course you can…right? We challenge Conor and Dodi to tell the difference between Conor and Conor BOT all while uncovering how AI is transforming the life sciences. Uncover how AI is transforming the life sciences. Together with an AI-bot the pair explore the potential applications of AI in drug discovery, personalizing medical treatments, protein folding, and more. They also consider the ethical considerations required when developing AI models, as well as the need for emotional intelligence in AI systems. Keywords : AI, ethical dilemma, bias, misinformation, datasets, diagnostics, drug discovery, healthcare.…
 
Let's explore the remarkable colour-changing abilities of cephalopods. Joined by Dan Wilson from the Kostas Research Institute at Northeastern University, the team dive into the fascinating research behind the development of paints that respond to environmental stimuli, such as sunlight. They also discuss titanium dioxide and how it acts as a facilitator of the colour-changing process. Professor Alon Gorodetsky, Associate Professor of Chemical and Biomolecular Engineering at the University of California, Irvine, talks about his research on developing energy-responsive dyes to mimic the features of octopi. Discover the potential applications of these dyes from diagnostics to resource-constrained initiatives, and more. Listen in and discover this remarkable evolutionary adaptation and the incredible ingenuity of cephalopods.…
 
In this episode of Discovery Matters, hosts Dodi and Conor explore how synthetic biology can lead to transformative breakthroughs when it comes to dealing with global health problems. Through their conversation with Justin Vigar, a PhD student in Dr. Keith Pardee's lab at the University of Toronto in Canada, we learn how his team's paper-based diagnostic tool has the potential to provide faster, more cost-efficient, and accessible diagnostics for underserved locations. This is complemented by Amir Pandi and Tobi Erb's discussion of using AI and synthetic biology to develop new antimicrobial peptides. Show notes • U of T PhD student uses synthetic biology to create low-cost diagnostic tools . • Pandi, A., Adam, D., Zare, A. et al. Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides. Nat Commun 14, 7197 (2023). https://doi.org/10.1038/s41467-023-42434-9 • Khalek IS, et al. Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins. Sci Transl Med. 2024 Feb 21;16(735). https://doi.org/10.1126/scitranslmed.adk1867 • Josh A Goldstein, Jason Chao, Shelby Grossman, Alex Stamos, Michael Tomz, How persuasive is AI-generated propaganda?, PNAS Nexus, Volume 3, Issue 2, February 2024. https://doi.org/10.1093/pnasnexus/pgae034…
 
Tune in to Discovery Matters to see how we can drug the undruggable. Dodi and Conor talk to Mark Bray, a second year PhD student in the Bowman Lab at the University of Pennsylvania, about the concept of “drugging the undruggable” for drug discovery and development. They discuss advances in medical research which has enabled us to drug molecular targets that were previously inaccessible, and the strategies that are used to devise and find effective drugs. Vicky Richon, CEO at Entact Bio, elucidates the importance of a revolutionary “induced proximity” modality for unprecedented drug treatments. Listen to this episode to understand modern approaches to treating diseases and uncovering cures.…
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド

探検しながらこの番組を聞いてください
再生